Stem Cells Spin (WAR:SCS) Change In Receivables: zł0.01 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:SCS Stem Cells Spin SA WAR:SCS
39 GF Score
Price zł0.49
GF Value zł0.10
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Stem Cells Spin Change In Receivables?

Stem Cells Spin WAR:SCS +0.41% 39 Change In Receivables is zł0.01 Mil as of Mar. 2026. GuruFocus rates WAR:SCS with a GF Score™ of 39/100 and a GF Value™ of zł0.10 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Stem Cells Spin's change in receivables for the quarter that ended in Mar. 2026 was zł-0.00 Mil. It means Stem Cells Spin's Accounts Receivable increased by zł0.00 Mil from Dec. 2025 to Mar. 2026 .

Stem Cells Spin's change in receivables for the fiscal year that ended in Dec. 2025 was zł0.00 Mil. It means Stem Cells Spin's Accounts Receivable declined by zł0.00 Mil from Dec. 2024 to Dec. 2025 .

Stem Cells Spin's Accounts Receivable for the quarter that ended in Mar. 2026 was zł0.01 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Stem Cells Spin's Days Sales Outstanding for the three months ended in Mar. 2026 was 182.50.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Stem Cells Spin's liquidation value for the three months ended in Mar. 2026 was zł-2.60 Mil.

Stem Cells Spin  (WAR:SCS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Stem Cells Spin's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.014/0.007*91
=182.50

2. In Ben Graham's calculation of liquidation value, Stem Cells Spin's accounts receivable are only considered to be worth 75% of book value:

Stem Cells Spin's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.022-2.936+0.75 * 0.014+0.5 * 0.605
=-2.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stem Cells Spin Change In Receivables Related Terms

Stem Cells Spin Change In Receivables Historical Data

* Premium members only.

The historical data trend for Stem Cells Spin's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stem Cells Spin Change In Receivables Chart

Stem Cells Spin Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.11 0.05 0.00 0.13 0.00

Stem Cells Spin Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.02 -0.01 0.04 -0.00
WAR:SCS
39GF Score
Stem Cells Spin SA WAR:SCS
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Stem Cells Spin Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of zł0.01 Mil mean?
Stem Cells Spin (WAR:SCS) has a Change In Receivables of zł0.01 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Stem Cells Spin and its competitors.
Is Stem Cells Spin's Change In Receivables too high?
Stem Cells Spin's current Change In Receivables is zł0.01 Mil. Overall, Stem Cells Spin has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stem Cells Spin's Change In Receivables compare to VRTX and REGN?
Stem Cells Spin's Change In Receivables of zł0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Stem Cells Spin and its competitors. Stem Cells Spin's current Change In Receivables is zł0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stem Cells Spin stock overvalued right now?
Based on GuruFocus' analysis, Stem Cells Spin (WAR:SCS) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.10, compared to a current price of zł0.49 — trading 390% above its estimated fair value. The current Change In Receivables is zł0.01 Mil. Stem Cells Spin's overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Stem Cells Spin (WAR:SCS), the current Change In Receivables is zł0.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Stem Cells Spin (WAR:SCS) Overvalued in 2026?

Based on GuruFocus' analysis, Stem Cells Spin stock appears to be overvalued. The current stock price of zł0.49 is trading 390% above its estimated GF Value™ of zł0.10. GuruFocus considers Stem Cells Spin to be Significantly Overvalued.

Key valuation signals for WAR:SCS:

  • Change In Receivables: zł0.01 Mil
  • GF Value™: zł0.10 vs. price of zł0.49 (390% above fair value)
  • GF Score™: 39/100 with 5 warning signs

No single metric tells the full story. See the WAR:SCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Stem Cells Spin Business Description

Address Ulica Konopnickiej 15 b, Wroclaw, POL, 51-141
Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing, and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1, and Velvetyna.
39GF Score

Get the complete analysis for WAR:SCS

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł0.49
Price
zł0.10
GF Value